Insulin Glargine市場按類型、糖尿病類型、分銷管道和地區分類

Insulin Glargine Market, By Type, By Diabetes Type, By Distribution Channel, By Geography

出版日期: 2025年02月20日 | 出版商:

Coherent Market Insights | 英文 167 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球Insulin Glargine市場規模估計為 58.1 億美元，預計到 2032 年將達到 90.9 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 6.6%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	58.1億美元
效能資料	2020-2024	預測期	2025-2032
預測期：2025 年至 2032 年複合年成長率	6.60%	2032 年金額預測	90.9 億美元

數字。 2025 年Insulin Glargine市場佔有率（按地區分列）

Insulin Glargine，也稱為 Lantus，是一種用於治療糖尿病的長效基礎胰島素。它是透過重組 DNA 技術製成的合成人類胰島素，可溶解於酸性環境中。注射後，它會在皮下組織中沉澱形成結晶，然後形成儲存庫，胰島素會從儲存庫逐漸被吸收到血液中。這種緩釋性和作用持續時間的特性可以為 1 型和 2 型糖尿病患者提供 24 小時的血糖值控制，每日一次即可。與其他基礎胰島素製劑Insulin Detemir和中性胰島素相比，Insulin Glargine的吸收速度較慢，有助於維持血液中更平穩、更一致的胰島素水平。

市場動態

全球Insulin Glargine市場的成長受到全球糖尿病盛行率上升的推動。國際糖尿病聯盟 (2021) 估計，2021 年將有超過 5.37 億成年人患有糖尿病，預計到 2030 年這一數字將增至 6.43 億，到 2045 年將增至 7.83 億。老年人口的增加也促進了市場的成長，因為糖尿病在老年人口中更為普遍。然而，成本限制是一個限制因素，尤其是在發展中國家。從積極的一面來看，更有效、更便捷的藥物傳輸技術的開發正在創造新的機會。

研究的主要特點

本報告對全球Insulin Glargine市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球Insulin Glargine市場的主要企業概況。
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球Insulin Glargine市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過全球Insulin Glargine市場分析中使用的各種策略矩陣更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 5.81 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.60%	2032 Value Projection:	USD 9.09 Bn

Insulin glargine, also known as Lantus, is a long-acting basal insulin that is used for the treatment of diabetes mellitus. It is a synthetic form of human insulin created through recombinant DNA technology, engineered to be soluble in acidic environments. Upon injection, it precipitates and forms microcrystals in the subcutaneous tissue, creating a depot from which insulin is gradually absorbed into the bloodstream. This extended release and duration of action profile allows once-daily dosing to help control blood glucose levels in patients with type 1 and type 2 diabetes over 24 hours. Insulin glargine has a slower absorption profile as compared to other basal insulins such as insulin detemir and insulin NPH, and thus, provides a smooth and consistent level of insulin in the blood.

Market Dynamics:

Global insulin glargine market growth is driven by growing prevalence of diabetes worldwide. According to estimates by the International Diabetes Federation 2021, over 537 million adults lived with diabetes in 2021, and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Increasing geriatric population also contributes to market growth since diabetes is more common in older age groups. However, cost constraints, especially in developing countries, acts as a restrain. On the positive side, ongoing development of more effective and convenient drug delivery technologies is expected to present new opportunities.

Key Features of the Study:

This report provides in-depth analysis of the global insulin glargine market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global insulin glargine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Sanofi, Biocon, Eli Lilly and Company, Boehringer Ingelheim, Gan & Lee, Kalbe Pharma, Polus Biopharm, Samsung Bioepis, Wockhardt, Novo Nordisk AS, Julphar, and Viatris Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.

Detailed Segmentation

Type:
- Lantus
- Basaglar
- Toujeo
- Soliqua/Suliqua
- Others
Diabetes Type:
- Type 2 Diabetes
- Type 1 Diabetes
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Company Profiles:
- Sanofi
- Biocon
- Eli Lilly and Company
- Boehringer Ingelheim
- Gan & Lee
- Kalbe Pharma
- Polus Biopharm
- Samsung Bioepis
- Wockhardt
- Novo Nordisk AS
- Julphar
- Viatris Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Diabetes Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing prevalence of diabetes worldwide
- High cost of insulin glargine
- Increase in awareness about diabetes management
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Insulin Glargine Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Insulin Glargine Market, By Type, 2020-2032, (USD BN)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Lantus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Basaglar
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Toujeo
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Soliqua/Suliqua
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

6. Global Insulin Glargine Market, By Diabetes Type, 2020-2032, (USD BN)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

7. Global Insulin Glargine Market, By Distribution Channel, 2020-2032, (USD BN)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

8. Global Insulin Glargine Market, By Region, 2020-2032, (USD BN)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
North America
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD BN)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biocon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gan & Lee
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Kalbe Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Polus Biopharm
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Samsung Bioepis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Wockhardt
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Julphar
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies